Log in to save to my catalogue

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an i...

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2740839194

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)

About this item

Full title

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2022-12, Vol.23 (12), p.1508-1516

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundStereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma, for which long-term data are awaited. The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma. MethodsThis study was an individual patient data meta-anal...

Alternative Titles

Full title

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2740839194

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2740839194

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(22)00656-8

How to access this item